Depo-Provera Settlement Amounts 2026: Payout Tiers, MSA & Case Value
Depo-Provera settlement amounts are now being discussed in the context of a real private settlement program in MDL 3140, but the public court record does not disclose an individual payout matrix, claimant-specific values or the complete eligibility criteria in the Master Settlement Agreement (MSA).
As of the August 3, 2026 JPML report, 6,294 actions were pending in MDL 3140. The court’s July 27 Case Management Order No. 12 says settlement registration was expected to be completed in November 2026 and that payments were expected to begin rolling out by the first quarter of 2027. BrownGreer was appointed Settlement Administrator on August 5.
Primary-source checks: CMO 12 · CMO 13 · Aug. 3 JPML report
Latest Depo-Provera Settlement Amounts and MDL 3140 Status
Federal Depo-Provera product-liability cases are centralized in MDL 3140 before Judge M. Casey Rodgers in the U.S. District Court for the Northern District of Florida. The August 3, 2026 JPML report listed 6,294 pending actions and 6,394 historical actions.
Depo-Provera Settlement Amounts: What Is Public vs. What Remains Private
This is the key distinction for understanding current Depo-Provera settlement amounts. Court orders confirm the existence and administration of the settlement, while the MSA itself remains private.
What Public Court Records Confirm
- A settlement of a majority of MDL and New York claims was announced June 15, 2026.
- The parties signed the MSA on July 21, 2026.
- The parties estimated roughly 80% of MDL plaintiffs would be eligible.
- BrownGreer was appointed Settlement Administrator on August 5.
- Settlement registration was represented as being completed in November 2026.
- Payments were represented as beginning to roll out by Q1 2027.
- MDL 3140 remains active for claims that are ineligible for, or do not resolve through, the settlement.
What Is Not Publicly Disclosed
- The complete MSA eligibility criteria.
- An official per-person payout matrix.
- Claimant-specific settlement amounts.
- The complete allocation methodology or point system, if any.
- Net payment calculations after liens, fees, expenses or other deductions.
- Whether any specific prospective claimant will qualify.
Illustrative Depo-Provera Settlement Amounts by Injury Tier
The following ranges are TortAdvisor editorial planning estimates. They are not official averages, not court-approved tiers and not values disclosed by the private MSA. An actual settlement result may be lower, higher or zero.
Severe or Permanently Disabling Claim
- Complex surgery, radiation or recurrent meningioma
- Permanent neurological, cognitive, vision, hearing or seizure-related impairment
- Substantial future care, disability or lost earning capacity
- Strong product-use, diagnosis, treatment and damages documentation
Surgery or Moderate-Impact Claim
- One significant surgery or substantial treatment burden
- Persistent symptoms, recovery limitations or meaningful wage loss
- Documented injection history and consistent medical timeline
- Ongoing surveillance, rehabilitation or impairment
Lower-Impact Documented Meningioma Claim
- Confirmed meningioma with lower treatment burden
- Monitoring or comparatively limited medical expense
- Less severe documented impairment or economic loss
- Claim-specific proof and causation issues still materially affect value
How TortAdvisor Estimates Depo-Provera Settlement Amounts
The editorial model organizes publicly observable claim-value factors rather than attempting to reverse-engineer the confidential MSA. It is intended to help readers understand what kinds of evidence generally affect damages analysis.
Injury Severity
Tumor characteristics, surgery, radiation, recurrence, neurological effects, disability, prognosis and future care.
Proof of Use
Injection records, pharmacy records, clinic records, insurer records, frequency and duration of Depo-Provera use.
Economic Loss
Medical expenses, lost wages, reduced earning capacity, disability, caregiving and future-care needs.
Litigation Risk
Causation evidence, Rule 702 rulings, preemption, jurisdiction, limitations defenses and defendant-specific issues.
Depo-Provera Settlement Amounts by Claim Profile
| Claim Profile | Editorial Range | Factors That May Raise Value | Factors That May Reduce Value |
|---|---|---|---|
| Lower-impact documented meningioma | $100,000–$300,000 | Clear product-use records, documented diagnosis, continuing surveillance, symptoms and measurable economic loss. | Limited treatment, incomplete product records, low documented loss, competing causation or deadline problems. |
| Surgery / moderate-impact injury | $300,000–$750,000 | Craniotomy, persistent neurological symptoms, rehabilitation, wage loss and strong use-and-diagnosis records. | Successful recovery, weaker economic damages, evidentiary gaps or legal defenses. |
| Severe / permanently disabling injury | $750,000–$1.5M+ | Recurrence, multiple procedures, permanent neurological loss, disability, future care and substantial earning-capacity loss. | Causation disputes, alternative causes, documentation gaps, jurisdictional issues or limitations defenses. |
These are not MSA tiers. The table is an editorial comparison model only.
Who May Qualify for the Depo-Provera Settlement?
The complete MSA eligibility criteria are private. The public court record says the eligibility terms in the MSA govern participation and that the parties estimated roughly 80% of MDL plaintiffs would be eligible. TortAdvisor cannot determine MSA eligibility from public information alone.
Public Litigation Screening Factors
- Documented use of Depo-Provera or injectable medroxyprogesterone acetate
- Intracranial meningioma diagnosis
- Medical imaging, pathology, neurology or neurosurgery documentation
- Pharmacy, clinic, OB/GYN, insurer or injection records
- A clear use-to-diagnosis timeline
- Documented treatment, impairment and economic damages
Issues That Still Require Individual Review
- Whether the private MSA actually covers the claimant
- Manufacturer or product-identification questions
- Incomplete use or diagnosis records
- Statute-of-limitations or jurisdiction issues
- Causation disputes or competing medical explanations
- Prior releases, settlements or litigation affecting rights
For evergreen legal and eligibility research, use the Depo-Provera lawsuit guide. For the latest MSA/news developments, use the current Depo-Provera settlement update.
Factors That May Increase or Reduce Depo-Provera Settlement Amounts
Duration and Frequency of Use
Longer and better-documented injection histories may strengthen exposure proof, but duration alone does not establish causation or MSA eligibility.
Tumor Severity and Location
Size, location, recurrence and effects on cognition, vision, hearing, balance or other neurological function can materially affect damages.
Treatment Intensity
Craniotomy, radiation, hospitalization, rehabilitation and future surveillance can increase documented medical damages.
Permanent Impairment
Seizures, cognitive changes, disability, loss of independence and future-care needs can materially affect valuation.
Economic Damages
Medical expenses, lost earnings, reduced earning capacity, caregiving, travel and future-care costs should be documented.
Legal and Scientific Proof
Product identification, expert evidence, general causation, preemption, jurisdiction and filing deadlines can strengthen or reduce a claim.
Evidence That Can Affect Depo-Provera Settlement Amounts
Product-Use Records
- Pharmacy and prescription records
- OB/GYN or clinic injection logs
- Insurance explanation-of-benefits records
- Dates and duration of injections
Medical Records
- MRI and CT imaging
- Pathology and operative reports
- Neurology and neurosurgery notes
- Radiation, rehabilitation and follow-up records
Damages Documentation
- Medical bills and insurance statements
- Wage and employment records
- Disability and future-care evidence
- Travel, caregiving and household-service costs
Settlement Registration and Depo-Provera Filing Deadlines
CMO 12 says the parties represented that settlement registration should be completed in November 2026, with payments beginning to roll out by Q1 2027. That administrative timeline is different from statutes of limitation or other legal filing deadlines.
Estimate Factors Affecting Depo-Provera Settlement Amounts
Use the calculator to organize diagnosis severity, product-use history, treatment, impairment and economic loss. The result is educational and does not reproduce the private MSA’s allocation methodology.
Before You Start
- Have approximate injection dates available.
- Know the diagnosis and treatment history.
- Gather major medical expenses and wage loss.
- Treat the output as an editorial planning estimate only.
Depo-Provera Settlement, MDL 3140, FDA & Medical Sources
Confirmed settlement and litigation statements are based primarily on federal court and JPML materials. FDA and peer-reviewed studies provide medical context and do not establish individual causation.
CMO 12 — Settlement Status
Open Case Management Order No. 12 →
Primary source for the June 15 settlement announcement, July 21 MSA, roughly 80% eligibility estimate, confidentiality and projected registration/payment timeline.
CMO 13 — BrownGreer
Open Case Management Order No. 13 →
August 5 order appointing BrownGreer PLC as Settlement Administrator.
JPML — August 3, 2026
Official source for the 6,294 pending / 6,394 historical MDL 3140 action count.
Northern District of Florida — MDL 3140
Current hearing dates, court information and master-docket resources.
JPML Transfer Order
February 7, 2025 order centralizing the litigation in the Northern District of Florida before Judge M. Casey Rodgers.
FDA Prescribing Information
Current federal prescribing information containing meningioma warning and monitoring/discontinuation language.
BMJ / PubMed — 2024 Study
French national case-control research evaluating selected progestogens and intracranial meningioma requiring surgery.
U.S. DMPA Study
U.S. population-based research examining depot medroxyprogesterone acetate and meningioma diagnosis.
2026 Danish Study
Population-level research evaluating contraceptive progestogens and incident meningioma.
Frequently Asked Questions About Depo-Provera Settlement Amounts
What is the average Depo-Provera settlement amount?
No reliable public average has been disclosed. A private settlement program exists, but the MSA’s claimant-specific payout values and allocation methodology are not public. TortAdvisor’s ranges are editorial estimates, not historical averages or MSA tiers.
Has a Depo-Provera settlement been announced?
Yes. CMO 12 states that leadership counsel announced a settlement of a majority of MDL and New York claims on June 15, 2026, and that the parties signed the private MSA on July 21.
How many Depo-Provera lawsuits are pending?
The August 3, 2026 JPML report lists 6,294 pending actions in MDL 3140 and 6,394 historical actions.
Who qualifies for the Depo-Provera settlement?
The complete MSA eligibility criteria are private. The parties estimated that roughly 80% of MDL plaintiffs would be eligible, but public information cannot determine whether a particular person qualifies.
Who is administering the Depo-Provera settlement?
BrownGreer PLC was appointed Settlement Administrator by the federal court on August 5, 2026.
When are Depo-Provera settlement payments expected?
CMO 12 says the parties represented that registration should be completed in November 2026, with payments beginning to roll out by the first quarter of 2027.
Are TortAdvisor’s payout tiers the official settlement amounts?
No. The tiers are editorial planning estimates. The private MSA’s individual payout structure has not been publicly disclosed.
Is the Depo-Provera settlement calculator legally binding?
No. The calculator provides an educational estimate from limited inputs and does not establish MSA eligibility, create an attorney-client relationship or guarantee compensation.
Use the Depo-Provera Settlement Calculator
Estimate a preliminary educational range based on diagnosis, treatment, injection history, impairment, evidence and economic loss.
